While antibody binder design has been transformed by protein foundation models, the subsequent development stages to turn those binders into drugs remain dependent on empirical, trial-and-error processes. Lead optimization, cell line development, and process development still rely on screening large numbers of candidates, clones, or conditions, with little ability to predict which will succeed. As pipelines shift toward bispecifics and other complex formats, that approach is getting harder to sustain.
In this GEN webinar, Asimov’s co-founder and CEO Alec Nielsen, PhD, will show how Asimov combines bio-foundation models, AI agents, and synthetic biology to augment development workflows. He will highlight how scientists use Kernel, Asimov’s model-driven computer-aided genetic design software, to automate critical genetic design tasks, and how AI agents can take on custom genetic designs for less common requirements.
Through a series of case studies, he will also demonstrate how agentic AI and other computational models can influence multiple areas of biologics development. Key takeaways from the webinar include: